via Neuroscience News
James Bibb, Ph.D., and colleagues have described a novel preclinical drug that could have the potential to combat depression, brain injury and diseases that impair cognition. The drug, which notably is brain-permeable, acts to inhibit the kinase enzyme Cdk5.
Cdk5 is a crucial regulator of signaling in brain neurons. Over three decades of study, it has been implicated in neuropsychiatric and neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease. Knocking out the enzyme in mice makes them resilient to stress, enhances their cognition, protects neurons from stroke and head trauma, and lessens neurodegeneration.
While inhibitors of Cdk5 could offer potential therapeutic benefits and new ways to study basic brain function, previous first- and second-generation anti-Cdk5 compounds largely get blocked at the blood-brain barrier that restricts movement of solutes from the blood to the central nervous system’s extracellular fluid. To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases.
Bibb and colleagues now report details of their anti-Cdk5, brain-permeable compound, 25-106. They also show that systemic administration of 25-106 alters neurobehavior in mice, reducing anxiety-like behavior.
“As perhaps the first robust systemic inhibitor, 25-106 represents an exciting and expandable and translatable pharmacological tool to study the function of Cdk5 activity in wild-type animals,” said Bibb, a professor in the University of Alabama at Birmingham Department of Surgery. “Achieving systemic applicability may be considered a step forward toward the testing of Cdk5 inhibitors to treat neuropsychiatric and neurodegenerative diseases. This provides a promising landscape for future studies to assess the effects of brain-permeable Cdk5 inhibitors to combat stress, anxiety, depression, addiction, cancer and neurodegeneration.”
The study, “Systemic administration of a brain permeable Cdk5 inhibitor alters neurobehavior,” is published in the journal Frontiers in Pharmacology.
In the paper, researchers describe synthesis of the aminopyrazole-based inhibitor, and they used molecular modeling to show that 25-106 appears to occupy the same hydrophobic binding pocket as the well-established Cdk5 inhibitor roscovitine.
They showed that 25-106 inhibited Cdk5 activity in a dose-dependent manner in brain striatal slices ex vivo, and that it also penetrated the brain after systemic administration in mice to inhibit Cdk5 in vivo. They measured the pharmacokinetic and pharmacodynamic parameters of 25-106 in blood plasma and the brains of mice, and the off-target distribution of 25-106 in the liver and kidneys.
Mice given systemic 25-106 showed modulated neurobehavior in the open field maze test and the tail suspension test, anxiolytic changes that have previously been linked to Cdk5 knockout mice.
They found that 25-106 is a non-selective inhibitor of both Cdk5 and another cyclin-dependent kinase, Cdk2, but note that very low levels of Cdk2 are found in the brain. However, any off-target or toxic effects of systemic inhibition of Cdk2 by 25-106 remain unknown.
Original Article: Novel preclinical drug could have potential to combat depression, brain injury and cognitive disorders
More from: University of Alabama Birmingham | University of Nebraska Medical Center
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
25-106 compound
- Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2024 Earnings Call Transcript
May 8, 2024 Teva Pharmaceutical Industries Limited misses on earnings expectations. Reported EPS is $-0.12161 EPS, expectations were $0.51. Teva Pharmaceutical Industries Limited isn’t one of the 30 ...
- In Vitro Diagnostics (IVD) Market Size to Reach USD 202.9 Billion By 2032, at 7.4% CAGR: Dimension Market Research
The Global In Vitro Diagnostics (IVD) market was valued at USD 106.9 Billion in 2023 which is further expected to reach USD 202.9 Billion in 2032 at a CAGR of 25.2%. In vitro diagnostics ... This ...
- Compound Interest Calculator
See how your savings and investment account balances can grow with the magic of compound interest. Many or all of the products featured here are from our partners who compensate us. This ...
- Best compound interest accounts
The best compound interest accounts perform the wonderful trick of earning money on your money. This is especially useful in today’s high-rate environment, and for anyone who tried to save over ...
- Thunder 106, Pelicans 85: Brandon Ingram 19 points | Game 3 postgame wrap
For a second straight meeting, Oklahoma City built a big lead and rolled to victory, this time spoiling the Pelicans’ first home playoff game since 2022.
Go deeper with Google Headlines on:
25-106 compound
[google_news title=”” keyword=”25-106 compound” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Cdk5 inhibitors
- DPP-4 Inhibitors -- An Update on Alogliptin
Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...
- ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What's the Evidence?
Although angiotensin-converting enzyme inhibitors are frequently used as antihypertensive agents to lower blood pressure and slow progression of nephropathy in patients with type 2 diabetes ...
- Clinical applications of angiogenic growth factors and their inhibitors
Promoting the formation of new collateral vessels in ischemic tissues using angiogenic growth factors (therapeutic angiogenesis) is a an exciting frontier of cardiovascular medicine. Conversely ...
- Breast Cancer Hormone Therapy Side Effects? What Helps
Many people who’ve had breast cancer take medications – tamoxifen or aromatase inhibitors – to help prevent the cancer from coming back. Doctors prescribe them for people with “hormone ...
- How do JAK inhibitors work for ulcerative colitis?
JAK inhibitors are oral medications that can help reduce the overactive immune response associated with ulcerative colitis (UC). UC is a type of inflammatory bowel disease (IBD) that causes ...
Go deeper with Google Headlines on:
Cdk5 inhibitors
[google_news title=”” keyword=”nano factory” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]